The decision to allow a new trial could have  implications for both the companies and families with babies born prematurely.

Today, Benzinga 's options scanner spotted 10 uncommon options trades for Abbott Laboratories. This isn't normal. The overall ...

Abbott Laboratories is undervalued with strong growth in diabetes care and weight-loss markets. Discover why ABT stock is a ...

Abbott Laboratories' medical device business is executing well, with double-digit growth in structural heart and diabetes.

Abbott Laboratories closed 10.57% short of its 52-week high of $141.23, which the company reached on March 4th.

We recently published a list of 10 Best Diabetes Stocks To Buy According to Billionaires. In this article, we are going to take a look at where Abbott Laboratories (NYSE:ABT) stands against other best ...

We recently published a list of Friday’s 10 Worst Performing Stocks. In this article, we are going to take a look at where ...

Whales with a lot of money to spend have taken a noticeably bullish stance on Abbott Laboratories. If we consider the ...

Shares of Abbott Laboratories and Reckitt Benckiser fell Friday after a judge ruled a new trial could be heard involving a case on their infant formula products that had already seen a ruling in their ...

Abbott Laboratories (NYSE:ABT – Free Report) had its price objective boosted by The Goldman Sachs Group from $138.00 to ...

Back in October, a jury found North Chicago-based Abbott and Reckitt’s formula subsidiary Mead Johnson not responsible for a ...

Abbott (ABT) reported Q4 EPS of $1.03, $0.11 better than the analyst estimate of $0.92. Revenue for the quarter came in at $10.1 ...